fbpx
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

View All News
February 19, 2021

Scout Bio to Present at the BofA Securities 2021 Animal Health Summit

PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE)Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions, today announced that Mark Heffernan, Scout Bio’s Chief Executive Officer, will present at the upcoming BofA Securities 2021 Animal Health Summit on Thursday, February 25, 2021 at 2:35 p.m. ET.

About Scout Bio
Scout Bio is a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions. Scout Bio’s therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio has a research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, a leader in the field of genetic medicine research. Scout Bio is a private company headquartered in Philadelphia, Pennsylvania. For more information, see www.scoutbio.co

For further information, please contact:

Investors:

Sarah McCabe
Stern Investor Relations, Inc.
212.362.1200
sarah.mccabe@sternir.com

Media:

Fran Gaconnier
Scout Bio
214.417.4142
fran.gaconnier@scoutbio.co

  • News

Scout Bio Expands Gene Therapy Collaboration with the University of Pennsylvania Via Next-Generation Vector Technologies

Partnership agreement includes exclusive rights in animal health to novel viral vector capsid and expands additional option rights to novel capsids Next-generation novel adeno-associated viral (AAV) vector capsid promises…

  • News

Scout Bio Named Best New Start-Up for 2021

IHS Markit recognizes Scout Bio for pioneering therapies in companion animal medicine PHILADELPHIA, November 08, 2021 — Scout Bio, a biotechnology company focused on one-time AAV gene therapies for…

  • News

Scout Bio Initiates Multi-Center Clinical Study of Gene Therapy for Chronic Arthritis Pain In Cats

– First vectorized antibody gene therapy to be studied in pets – Strong initial in-species data support therapeutic profile of one-time gene therapy designed for long-term pain management –…